Genoptix Announces Participation at 28th Annual J.P. Morgan Healthcare Conference

CARLSBAD, Calif., Jan. 4 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company's participation at the 28th Annual J.P. Morgan Healthcare Conference to be held at the Westin St. Francis Hotel in San Francisco, Calif. on January 11-14, 2010.

Dr. Tina S. Nova, President and CEO of Genoptix, and Sam Riccitelli, Genoptix's EVP and COO, will present at the conference on Monday, January 11, 2010 beginning at approximately 2:30 p.m. PST, when they will provide an overview of the Company's specialized diagnostic laboratory services business, growth strategies and financial performance.

The presentation is expected to last approximately 30 minutes which will be web cast live and made accessible through the "Investors" section of the Genoptix website at www.genoptix.com. Those who would like to listen to the presentation should go to this site at least 15 minutes prior to the event to register, download and install any necessary software. An audio replay and copy of the presentation will also be available for 30 days following the initial presentation web cast.

About Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Founded in 1999, Genoptix completed its initial public offering in November 2007 and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.

SOURCE Genoptix, Inc.